Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease

Committee for Medicinal Products for Human Use (CHMP) Grants Accelerated Assessment

FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease

CAMBRIDGE, Massachusetts -

- FDA Issued Action Date of February 28, 2010 Under the Prescription Drug User Free Act (PDUFA)

New Shire Board Member

DUBLIN, Ireland - The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that Mr David Stout joined the Board as a Non Executive Director with effect from 31 October 2009.

Shire Continues to Deliver Excellent Growth From Core Products

DUBLIN - Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease

DUBLIN -

- FOSRENOL(R) (lanthanum carbonate) Now Approved in the EU to Treat hyperphosphataemia >1.78mmol/L in Chronic Kidney Disease Patients Not on Dialysis

FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity

DUBLIN - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R). The five-year exclusivity period for VYVANSE expires on February 23, 2012. VYVANSE is covered by United States patents which remain in effect until June 29, 2023.

Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA

CAMBRIDGE, Massachusetts -

- Early Access for Fabry Patients Available Under Treatment Protocol and Emergency IND

Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)

PHILADELPHIA -

- Settlement Ends all Litigation With Generics Over ADDERALL XR(R)

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. (”Sandoz”) in connection with Sandoz’s Abbreviated New Drug Application (”ANDA”) and its attempt to market generic versions of Shire’s ADDERALL XR(R) (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder.

Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today

DUBLIN -

- For Medical and Healthcare Media Only -

- Direct Comparison of the Two non-Calcium Phosphate Binders Gives new Insights Into Relative Efficacy

Update on Velaglucerase Alfa

CAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is committed to doing everything possible to assist Gaucher patients and their physicians during the imiglucerase supply shortage. Shire is pleased to be able to provide velaglucerase alfa well over a year ahead of previously anticipated commercial launch world wide.

Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17

PHILADELPHIA -

- INTUNIV, the First Nonscheduled alpha-2A receptor agonist indicated for ADHD, Demonstrated Improvement in a Range of ADHD Symptoms That can be Disruptive, Such as Inattention, Arguing With Adults, Hyperactivity, Impulsivity, and Losing One’s Temper

Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials

CAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today reported that it has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease, with the U.S. Food and Drug Administration (FDA). The Company also announced positive results from the final two Phase III studies of velaglucerase alfa, with both studies reaching all of their primary and secondary endpoints.

Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform

CAMBRIDGE, Massachusetts -

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development.

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

LONDON -

- 2009 Guidance Framework Reaffirmed

Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009.

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

LEXINGTON, Massachusetts -

- Treatment Protocol Accepted and Rolling Submission of New Drug Application Initiated

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

PHILADELPHIA - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date.

Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease

LEXINGTON, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type I Gaucher disease. Shire is working with the FDA to determine subsequent steps and timing for the filing of its NDA.

Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease

LEXINGTON, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that, at the request of the FDA, in view of a potential restriction on the availability of the current approved and marketed treatment for Gaucher Disease patients, it has filed a treatment protocol for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Gaucher Disease.

A Supplement a Day May Help Keep Falls at Bay

BASINGSTOKE, England -

- Help is at Hand for the Frail Elderly at Risk of Falls and Fractures via a New Medication Support Programme

Shire begins the year with a strong performance

PHILADELPHIA and DUBLIN - Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to March 31, 2009.

Shire plc: Results of the Annual General Meeting Held on April 28, 2009

DUBLIN - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009

DUBLIN, Ireland - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce first quarter 2009 earnings on Thursday April 30, 2009.

Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents

PHILADELPHIA - Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court for the Southern District of New York against Natco Pharma Limited (”Natco”) for infringement of two of Shire’s patents: U.S. Patent No. 5,968,976 (”‘976 Patent”); and U.S. Patent No. 7,381,428 (”‘428 Patent”);